Business, energy, technology, markets and global industry news from Business News Today

Johnson & Johnson

PharmaDeviceNews Johnson & Johnson
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More
Representative image of immunology research and clinical trial analysis, reflecting Johnson & Johnson’s growing nipocalimab strategy in lupus and Sjögren’s disease.
Pharma & Biotech

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Read More
Representative image: An oncologist reviews lung scan and precision medicine data, reflecting how Rybrevant plus Lazcluze could reshape first-line treatment expectations for atypical EGFR-mutated non-small cell lung cancer.
Pharma & Biotech

Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Read More
Representative image showing a clinician reviewing joint health with a patient, reflecting Johnson & Johnson’s Tremfya FDA label expansion for structural joint damage inhibition in active psoriatic arthritis.
Pharma & Biotech

Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

Read More
Medical Devices & Diagnostics

Why DePuy Synthes’ Gemtrack deal could reshape navigation in hip, knee and shoulder surgery

DePuy Synthes wants to remove a robotics bottleneck. Its Gemtrack deal could change joint surgery navigation if regulators agree.

Read More
Representative image of a robotic-assisted soft tissue surgery setting, highlighting how Johnson & Johnson’s OTTAVA pivotal gastric bypass study could intensify competition in advanced surgical robotics.
Medical Devices & Diagnostics

Johnson & Johnson clears a key OTTAVA hurdle, but the harder robotics test comes next

Robotic surgery is opening up. Johnson & Johnson’s OTTAVA data may test whether hospitals want a new soft tissue platform.

Read More
Pharma & Biotech

Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?

Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.

Read More
Representative image of a clinical consultation on long-term schizophrenia care, as Johnson & Johnson’s CAPLYTA FDA label update sharpens focus on relapse prevention, treatment stability, and durability in neuropsychiatric therapy.
Pharma & Biotech

Johnson & Johnson’s CAPLYTA update raises the bar for long-term schizophrenia stability

Schizophrenia drugs face a durability test. CAPLYTA’s FDA update gives Johnson & Johnson a stronger long-term stability story.

Read More
Medical Devices & Diagnostics

Why Pulse Biosciences’ 12-month nsPFA data matters in a PFA market dominated by Farapulse and Affera

Boston Scientific owns the PFA market. Pulse Biosciences just posted 90% one-year AF freedom. Is nanosecond PFA a real disruption or an acquisition target?

Read More
Medical Devices & Diagnostics

Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?

See how Johnson & Johnson is using CARTOSOUND SONATA and VARIPULSE to reshape electrophysiology workflow and arrhythmia care. Read more.

Read More